Regeneron

News

Regeneron has refiled its CD20xCD3 bispecific odronextamab for lymphoma with the FDA, which was rejected last year, but is seeking a narrower label.

News

Ten out of 11 children with congenital deafness treated with a gene therapy developed by Regeneron have seen "notable" improvements in hearing.

News

The FDA is scheduled to deliver a verdict on Sanofi and Regeneron's Dupixent for rare autoimmune skin disorder bullous pemphigoid in June.

News

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project.

News

Regeneron has bought Oxular, a UK specialist in retinal diseases, in a move that bolsters its already strong position in ophthalmology therapies.

News

Regeneron's Alnylam-partnered poze-cemdi combination achieves greater disease control measured using LDH than AZ's market-leading Ultomiris.